HomeCompareRNAM vs ORCC

RNAM vs ORCC: Dividend Comparison 2026

RNAM yields 2.74% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RNAM wins by $2.4K in total portfolio value· pulled ahead in Year 4
10 years
RNAM
RNAM
● Live price
2.74%
Share price
$72.86
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.8K
Annual income
$327.66
Full RNAM calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — RNAM vs ORCC

📍 RNAM pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRNAMORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RNAM + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RNAM pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RNAM
Annual income on $10K today (after 15% tax)
$233.32/yr
After 10yr DRIP, annual income (after tax)
$278.51/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, RNAM beats the other by $277.63/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RNAM + ORCC for your $10,000?

RNAM: 50%ORCC: 50%
100% ORCC50/50100% RNAM
Portfolio after 10yr
$22.6K
Annual income
$164.35/yr
Blended yield
0.73%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

RNAM
Analyst Ratings
2
Buy
9
Hold
Consensus: Hold
Altman Z
23.7
Piotroski
2/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RNAM buys
0
ORCC buys
0
No recent congressional trades found for RNAM or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRNAMORCC
Forward yield2.74%9.79%
Annual dividend / share$2.00$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$23.8K$21.4K
Annual income after 10y$327.66$1.04
Total dividends collected$3.0K$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusHoldBuy

Year-by-year: RNAM vs ORCC ($10,000, DRIP)

YearRNAM PortfolioRNAM Income/yrORCC PortfolioORCC Income/yrGap
1$10,974$274.50$11,190$489.61$216.00ORCC
2$12,024$281.54$12,229$256.01$205.00ORCC
3$13,154$288.29$13,216$130.74$62.00ORCC
4← crossover$14,370$294.75$14,207$66.02+$163.00RNAM
5$15,677$300.92$15,234$33.17+$443.00RNAM
6$17,081$306.81$16,317$16.62+$764.00RNAM
7$18,589$312.42$17,468$8.32+$1.1KRNAM
8$20,208$317.77$18,695$4.16+$1.5KRNAM
9$21,945$322.84$20,006$2.08+$1.9KRNAM
10$23,809$327.66$21,407$1.04+$2.4KRNAM

RNAM vs ORCC: Complete Analysis 2026

RNAMStock

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

Full RNAM Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this RNAM vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RNAM vs SCHDRNAM vs JEPIRNAM vs ORNAM vs KORNAM vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.